Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital

Asia-Pacific Journal of Clinical Oncology

Volumn 9, Issue 2, 2013, Pages 169-175

  Alexander, Marliese ^a   Teoh, Khai C ^b   Lingaratnam, Senthil ^a   Kirsa, Sue ^a   Mellor, James D ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Immunomodulatory drugs; Lenalidomide; Multiple myeloma; Thalidomide; Thromboprophylaxis

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BORTEZOMIB; ENOXAPARIN; LENALIDOMIDE; RECOMBINANT ERYTHROPOIETIN; STEROID; THALIDOMIDE; WARFARIN;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEALTH SURVEY; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICAL SPECIALIST; MULTIPLE MYELOMA; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTICOAGULANTS; ASPIRIN; CANCER CARE FACILITIES; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; RETROSPECTIVE STUDIES; SPECIALIZATION; THALIDOMIDE; THROMBOSIS; WARFARIN;

EID: 84878189319     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12013     Document Type: Article

References (17)

1. Palumbo A, Facon T, Sonnerveld P etal. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111: 3968-3977.
2. Weber DM, Chen C, Niesvizky R etal. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009) [abstract]. J Clin Oncol 2006; 24: 427S.
3. Richardson PG, Blood E, Mitsiades CS etal. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458-3464.
4. Rajkumar SV, Hayman SR, Lacy MQ etal. Combination therapy with lenalidomide plus dexamethasone (rev/ dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-4053.
5. Musallam KM, Dahdaleh FS, Shamseddine AL etal. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res 2009; 123: 679-686.
6. Palumbo A, Rajkumar SV, Dimopoulos MA etal. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423.
7. Palumbo A, Cavo M, Brinthen S etal. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 2011; 29: 986-993.
8. Palumbo A, Rus C, Zeldis JB etal. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 2006: 1842-1845.
9. Larocca A, Cavallo F, Bringhen S Etal. Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide. Blood 2012; 119: 933-939.
10. Rajkumar SV, Gertz MA. Lenalidomide and venous thrombosis in multiple myeloma. Blood 2006; 108: 404.
11. Palumbo A, Bringhen S, Caravita T etal. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825-831.
12. Weber D, Rankin K, Gavino M etal. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
13. Cavo M, Tacchetti P, Patriarca F etal. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075-2085.
14. Baz R, Li L, Kottke-Marchant K etal. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80: 1568-1574.
15. Cavo M, Zamagni E, Tosi P etal. Superiority of thalidomide and dexamethasone over vincristinedoxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35-39.
16. Miller KC, Padmanabhan S, Dimicelli L etal. Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma 2006; 47: 2339-2343.
17. Commonwealth of Australia Department of Health and Aging. Pharmaceutical benefits scheme n.d. [Cited 5 Jun 2011]. Available from: http://www.pbs.gov.au/pbs/home.